TOFA molecule reduces body weight in mice by 18% without appetite suppression

The TOFA molecule, which targets fatty acid synthesis enzymes and nuclear receptors, reduced body weight in mice by approximately 18% over four weeks. The weight loss occurred in adipose tissue while muscle mass was preserved. These results were obtained exclusively in animal experiments; additional preclinical and clinical trials are required before human use. Mechanism of Action TOFA inhibits acetyl-CoA carboxylases ACC1 and ACC2, enzymes involved in the synthesis of fatty acids. Simultaneously, the molecule partially activates PPARα and PPARδ nuclear receptors, which regulate lipid and energy metabolism. Researchers suggest this combined action limits the formation of new lipids and stimulates the use of fat stores for energy. Unlike GLP-1 receptor agonists, which reduce food intake by suppressing appetite, TOFA works by increasing energy expenditure. In metabolic chambers, mice receiving the compound showed energy expenditure approximately 18% higher than the control group, while continuing to consume the same amount of food as before treatment.